Consumer medicine information




Brand name


Active ingredient





Consumer medicine information (CMI) leaflet

Please read this leaflet carefully before you start using Androderm.

What is in this leaflet

This leaflet answers some of the common questions about Androderm®. It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist.

All medicines have risks and benefits. Your doctor has weighed the possible risks of you using Androderm® against the benefits they expect it will have for you.

If you have any concerns about using this medicine talk to your doctor or pharmacist.

Keep this leaflet with the medicine. You may need to read it again.

What Androderm® is used for

Androderm® is used to replace testosterone in males when the body is unable to produce enough of its own. Testosterone is a hormone that is necessary for the normal development and maintenance of male reproductive tissues and other characteristic male traits.

Androderm® is a testosterone transdermal delivery patch. This means that when the patch is applied to the skin, the testosterone passes from the patch, through the skin and into the bloodstream.

The testosterone in Androderm® is identical to the naturally occurring testosterone present in the body.

Ask your doctor if you have any questions about why this medicine has been prescribed for you. Your doctor may have prescribed it for another reason.

This medicine is not addictive.

This medicine is available only with a doctor's prescription.

This medicine is not expected to affect your ability to drive a car or operate machinery.

There is not enough information to recommend the use of this medicine for children below the age of 15 years.

Before you use Androderm®

When you must not use it

Do not use Androderm® if you have an allergy to:

  • any medicine containing testosterone
  • any of the ingredients listed at the end of this leaflet.

Symptoms of an allergic reaction may include shortness of breath, wheezing or difficulty breathing; swelling of the face, lips, tongue or other parts of the body; rash, itching or hives on the skin.

Do not use this medicine if you are female.

Do not use this medicine if you have any of the following medical conditions:

  • known or suspected prostatic cancer (testosterone and other male hormones can speed up the growth of tumours of the prostate)
  • cancer of the breast
  • kidney disease (with protein in the urine)
  • high levels of calcium in the blood.

Do not use this medicine after the expiry date printed on the pack or if the packaging is torn or shows signs of tampering. If it has expired or is damaged, return it to your pharmacist for disposal.

If you are not sure whether you should start using this medicine, talk to your doctor.

Before you start to use it

Tell your doctor if you have allergies to any other medicines, foods, preservatives or dyes.

Tell your doctor if you have or have had any of the following medical conditions:

  • high blood pressure
  • epilepsy
  • migraines
  • heart disease
  • kidney or liver diseases
  • an enlarged prostate gland (signs may include difficulty passing urine or frequent passing of urine)
  • a tendency to retain fluid (signs may include swollen feet or ankles).
  • a previous blood clot in the legs or lungs

If you have not told your doctor about any of the above, tell him/her before you start using Androderm®.

Taking other medicines

Tell your doctor or pharmacist if you are taking any other medicines, including any that you buy without a prescription from your pharmacy, supermarket or health food shop.

Some medicines and Androderm® may interfere with each other. These include:

  • medicines used to prevent blood clots, such as warfarin, or other anticoagulants
  • medicines used to control blood sugar, such as insulin.

These medicines may be affected by Androderm® or may affect how well it works. You may need different amounts of your medicines, or you may need to use different medicines.

Your doctor and pharmacist have more information on medicines to be careful with or avoid while using this medicine.

How to use Androderm®

Follow all directions given to you by your doctor or pharmacist carefully. They may differ from the information contained in this leaflet.

If you do not understand the instructions on the label, ask your doctor or pharmacist for help.

How much to apply

The number of patches used may be different for different people. Usually one Androderm®5 mg/day Transdermal Patch, or two Androderm®2.5 mg/day Transdermal Patches, are applied to the skin once a day (if two Androderm®2.5 mg/day Transdermal Patches are used, they should not overlap one another). This will provide your body with approximately 5 milligrams of testosterone per day.

When to apply it

Apply Androderm® late in the evening (at approximately 10.00 pm). It is important to apply Androderm® in the evening, as this will provide your body with testosterone levels similar to those normally produced in the body.

Where to apply it

Always apply Androderm® to clean dry flat areas of skin. The best areas to use are the back, stomach, thighs and upper arms. The patch may not stick properly if applied to oily or hairy areas. If the skin is very hairy, the hair can be clipped (not shaved) so that the patch sticks well.

Never apply the patch to an area of skin that has sores, cuts or rashes.

Never apply the patch to the scrotum.

Avoid applying the patch to bony areas such as the point of the hip or shoulder. Application here can cause skin blisters.

Avoid applying the patch to the chest or shins. Application here may result in absorption of less testosterone.

Every day, remove the old patch and apply the new patch to a new area of skin. Avoid using the same skin site for at least seven days to reduce the risk of skin irritation.

How to apply it

Remove a pouch from the box and tear it open. Remove the patch from the pouch.

Hold the tabs on the patch and, whilst firmly holding the liner tab, gently peel the patch open.

Discard the liner.

Place the sticky side of the patch against the skin and press firmly around the edges so that the patch lies flat against the skin.

If a patch falls off before mid-day, replace it with a new patch on the same skin site. If the patch falls off later in the day do not replace it until the night time application (choose a new skin site). If a patch becomes loose, smooth it down and press your fingers around the edge of the patch.

When you take an old patch off, dispose of it by folding it in half with the sticky side inwards.

Dispose of it carefully in the household waste where children cannot reach it. Even a used patch will still contain some medicine.

If you miss a dose

If you forget to apply Androderm® in the evening, apply it as soon as you remember, providing this is before 12 noon the following day. Otherwise do not apply it until your next evening application time. Then carry on as usual.

If you use too much (overdose)

Remove the patches and immediately telephone your doctor or the Poisons Information Centre (telephone 13 11 26 in Australia, or call 0800 764 766 in New Zealand) for advice, or go to Accident and Emergency at your nearest hospital, If you think that you or anyone else may have used too much Androderm®. Do this even if there are no signs of discomfort or poisoning.

While you are using Androderm®

Things you must do

If you are about to be started on any new medicine, remind your doctor and pharmacist you are using Androderm®.

If you are undergoing an MRI scan, tell your doctor you are using Androderm®. Skin burns have been reported at the patch site in several patients wearing aluminised transdermal patches during a magnetic resonance imaging scan (MRI). Because Androderm® contains aluminium, it is recommended that you remove the patch before undergoing MRI.

Tell any other doctors, dentists and pharmacists who treat you that you are using this medicine.

Keep all of your doctor's appointments so that your progress can be checked. Your doctor will conduct regular examinations of your prostate gland during treatment with this medicine to detect unwanted side effects. Your doctor may also measure the level of testosterone in your blood to make sure the medicine is working.

Things you must not do

Do not use Androderm® to treat any other complaints unless your doctor tells you to.

Do not give your medicine to anyone else, even if they have the same condition as you.

Do not use the patch if it is damaged.

Do not cut Androderm® patches

Things to be careful of

When applied to clean dry skin, the patch is expected to remain in place during normal activities. Contact with water such as showering or swimming, should not affect the patch. Strenuous exercise or excessive perspiration may loosen the patch or cause it to fall off.

Do not heat the patch or press the reservoir too hard. The patch may burst if it is handled incorrectly.

Side effects

Tell your doctor or pharmacist as soon as possible if you do not feel well while you are using Androderm®.

This medicine helps most males with low testosterone levels, but it may have unwanted side effects in a few people. All medicines can have side effects. Sometimes they are serious, most of the time they are not. You may need medical treatment if you get some of the side effects.

If you are over 65 years of age you may have an increased chance of getting side effects.

Do not be alarmed by the following lists of side effects. You may not experience any of them.

Ask your doctor or pharmacist to answer any questions you may have.

Tell your doctor or pharmacist if you notice any of the following and they worry you:

  • skin irritation, for example rash or slight redness and itching of the skin where the patch has been. Mild skin irritation usually disappears within 3 to 4 days after removal of the patch. If skin irritation persists, your doctor or pharmacist may be able to help
  • acne where the patch has been
  • loss of head hair (male pattern baldness)
  • headache, confusion, tiredness, body pain
  • nausea, increased appetite
  • numbness, tingling or pins and needles
  • frequent or persistent erections, increased or decreased sex drive.
  • increase in weight

These side effects are usually mild and short-lived.

Tell your doctor as soon as possible if you notice any of the following:

  • more severe skin reactions such as blistering or contact dermatitis. This is a sign of allergy and your doctor may decide not to continue the use of Androderm®
  • swollen feet or ankles due to fluid retention
  • difficulty in passing urine, frequent passing of urine, loss of bladder control or blood in the urine
  • depressed mood, thinking abnormalities, anxiety.

The above list includes serious side effects which may require medical attention.

If any of the following happen, tell your doctor immediately or go to Accident and Emergency at your nearest hospital:

  • blood in the bowel motions (black tarry stools).
  • pain, swelling or redness in your legs
  • difficulty breathing or chest pain

The above list includes very serious side effects. You may need urgent medical attention or hospitalisation.

Tell your doctor or pharmacist if you notice anything else that is making you fell unwell. Other side effects not listed above may also occur in some people. Some of these side effects (for example a reduction in the number of sperm produced or high blood pressure) can only be found when your doctor does tests from time to time to check your progress.

After using Androderm®


Keep the patches in the original pack until it is time to use them. If you take the patches out of the pouch they will not keep well.

Keep the pack in a cool dry place where the temperature stays below 25 degrees C.

Do not store Androderm®or any other medicine in the bathroom or near a sink.

Do not leave it on a window sill or in the car. Heat and dampness can destroy some medicines.

Keep it where children cannot reach it. A locked cupboard at least one-and-a-half metres above the ground is a good place to store medicines.


If your doctor tells you to stop using this medicine or the expiry date has passed, ask your pharmacist what to do with any patches that are left over.

Dispose of used or damaged patches in the household garbage in a way that stops any pet, child, or other person from accidentally applying or swallowing them.

Product description

What it looks like

Androderm®2.5* mg/day Transdermal Patches are round, skin-toned patches with distinct concentric heat sealed rings.

Androderm®5 mg/day Transdermal Patches are elliptical ("egg-shaped") skin-toned patches with distinct heat sealed rings. (Available in Australia only)

Each Androderm® patch is packaged in a heat sealed pouch.


Each Androderm®2.5 mg/day Transdermal Patch contains 12.2 milligrams of testosterone and delivers 2.5 milligrams of testosterone over 24 hours.

It is available in packs of 60 patches.

* Not all strengths may be available

Each Androderm®5 mg/day Transdermal Patch contains 24.3 milligrams of testosterone and delivers approximately 5 milligrams of testosterone over 24 hours.

It is available in packs of 30 patches.

Other ingredients in the gel reservoir include:

  • ethanol,
  • purified water,
  • glycerol,
  • glyceryl monooleate,
  • methyl laurate,
  • carbomer copolymer (type B), and sodium hydroxide.

The adhesive substance is laminate AR-7584.


Australian Sponsor:

Teva Pharma Australia Pty Limited
Level 1
37 Epping Rd
Macquarie Park, NSW, 2113
1800 288 382

New Zealand Sponsor:

Teva Pharma New Zealand Limited
PO Box 128 244
Remuera Auckland 1541
Telephone: 0800 800 097

Australian Registration Numbers:

2.5 mg - AUST R 61818

5 mg - AUST R 82398

This leaflet was updated in October 2020.

Published by MIMS November 2020


Brand name


Active ingredient





1 Name of Medicine


2 Qualitative and Quantitative Composition

The structure of testosterone (17β-hydroxyandrost-4-en-3-one) is given below. The molecular weight of the compound is 288.4. Testosterone is a white crystalline powder, or colourless or yellowish-white crystals, practically insoluble in water, freely soluble in alcohol and in methylene chloride, practically insoluble in fatty oils.
Androderm provides continuous delivery of testosterone for 24 hours following application to intact, non-scrotal skin (e.g. back, abdomen, thighs, upper arms).
Two strengths of Androderm Transdermal Patch are available which deliver in vivo 2.5 mg or 5 mg of testosterone per day across skin of average permeability.
The Androderm 2.5 mg/day Transdermal Patch has a 7.5 cm2 active surface area and contains 12.2 mg testosterone USP. The Androderm 5 mg/day Transdermal Patch has a 15 cm2 active surface area and contains 24.3 mg testosterone USP.

Excipients with known effect.

For the full list of excipients, see Section 6.1 List of Excipients.

3 Pharmaceutical Form

Androderm is a transdermal drug delivery system consisting of a self adhesive patch surrounding a central drug reservoir of testosterone dissolved in an alcohol-based gel.

4 Clinical Particulars

4.1 Therapeutic Indications

Androderm is indicated for testosterone replacement therapy for confirmed testosterone deficiency in males.

4.2 Dose and Method of Administration

The usual dose is one Androderm 5 mg/day Transdermal Patch applied nightly (approximately 10.00 pm) and worn for 24 hours, providing approximately 5 mg testosterone per day.
The dose can be adjusted up to 7.5 mg/day (i.e. one 5 mg/day and one 2.5 mg/day patches or three 2.5 mg/day patches) nightly or down to 2.5 mg/day (i.e. one 2.5 mg/day patch) nightly depending on the serum testosterone measured in the morning after the application. Measurement of serum testosterone should be repeated taking care to ensure proper patch adhesion and correct time of application before the dose is adjusted.
Treatment in non-virilised patients may be initiated with one Androderm 2.5 mg/day Transdermal Patch applied nightly. The dose should be adjusted as appropriate.
Three patches per day may be required for men with a higher bodyweight (> 130 kg).
The duration of treatment and frequency of testosterone measurements is determined by the physician.
The adhesive side of the patch should be applied to a clean, dry area of the skin on the back, abdomen, upper arms, or thighs.
Bony prominences, such as the shoulder and hip areas, should be avoided as this may predispose to skin blister reactions. Absorption is more variable if applied to skin on the chest and shins.
Do not apply to the scrotum.
The sites of application should be rotated, with an interval of 7 days between applications to the same site. The area selected should not be oily, damaged or irritated.
The patch should be applied immediately after opening the pouch and removing the protective release liner.
The patch should be pressed firmly in place, making sure there is good contact with the skin, especially around the edges.
Damaged patches should not be used.
Androderm patches cannot be cut to deliver a smaller dose. Androderm is a transdermal drug delivery system consisting of a self-adhesive patch surrounding a central drug reservoir of testosterone dissolved in an alcohol-based gel. Androderm patches should not be cut as the reservoir contained in the patch would leak.

4.3 Contraindications

Known hypersensitivity to testosterone or other constituents of the patch.
Androgens are contraindicated in men with carcinoma of the breast or known or suspected carcinoma of the prostate, nephrotic syndrome and hypercalcaemia.
Androderm has not been evaluated in women and must not be used in women. Testosterone may be harmful to the foetus.

4.4 Special Warnings and Precautions for Use

Identified precautions.

Geriatric patients and others with an increased risk of developing prostatic hypertrophy and/or prostate cancer, should be assessed before starting testosterone replacement therapy because testosterone may promote the growth of the prostate and of subclinical prostate cancer. Patients receiving testosterone replacement therapy should be reviewed for prostatic disease in accordance with contemporary clinical practice for their age.
Hypercalciuria/ hypercalcaemia (caused by skeletal metastases) may be exacerbated by androgen treatment.
Testosterone may cause a rise in blood pressure and Androderm should be used with caution in patients with hypertension.
Oedema, with or without congestive heart failure, may result from androgen treatment in patients with pre-existing cardiac, renal, or hepatic disease. In addition to discontinuation of the drug, diuretic therapy may be required.
Androderm should be used with caution in patients with ischaemic heart disease, epilepsy and migraine as these conditions may be aggravated. Patients should be monitored for polycythemia and for sleep apnoea.

Clotting disorders.

Testosterone should be used with caution in patients with thrombophilia or risk factors for venous thromboembolism (VTE), as there have been post-marketing studies and reports of thrombotic events (e.g. deep-vein thrombosis, pulmonary embolism, ocular thrombosis) in these patients during testosterone therapy. In thrombophilic patients, VTE cases have been reported even under anticoagulation treatment, therefore continuing testosterone treatment after first thrombotic event should be carefully evaluated. In case of treatment continuation, further measures should be taken to minimise the individual VTE risk.

Use in the elderly.

No age related effects on testosterone pharmacokinetics were observed in clinical trials of Androderm in men up to 65 years of age. In a group of 9 elderly testosterone deficient men (65 to 79 years of age, average baseline testosterone level 184 ± 50 nanogram/dL), a single application of two Androderm 2.5 mg systems to the back resulted in an average testosterone level of 591 ± 121 nanogram/dL with a Tmax of 14.2 ± 4.2 hours. The total testosterone delivered over the 24 hour application time was 3.8 ± 0.6 mg, approximately 20% less than the average amount delivered in younger patients.

Paediatric use.

Androderm is not indicated for use in children as there has been no clinical experience of its use below the age of 15.

Effects on laboratory tests.

No data available.

4.5 Interactions with Other Medicines and Other Forms of Interactions

When used simultaneously with anticoagulants, the anticoagulant effect can increase. Patients receiving oral anticoagulants require close monitoring especially when androgens are started or stopped.
Concurrent administration of oxyphenbutazone and androgens may result in elevated serum levels of oxyphenbutazone.
In diabetic patients, the metabolic effects of androgens may decrease blood glucose and, therefore, insulin requirements.
Skin burns have been reported at the patch site in several patients wearing an aluminised transdermal system during a magnetic resonance imaging scan (MRI). Because Androderm contains aluminium, it is recommended to remove the system before undergoing an MRI.

4.6 Fertility, Pregnancy and Lactation

Androderm therapy has not been evaluated in and must not be used in women under any circumstances. Testosterone may have a virilising effect on the female foetus.

Effects on fertility.

No data available.
(Category D)
Category D: Drugs which have caused, are suspected to have caused or may be expected to cause, an increased incidence of human foetal malformations or irreversible damage. These drugs may also have adverse pharmacological effects.
No data available.

4.7 Effects on Ability to Drive and Use Machines

The effects of this medicine on a person's ability to drive and use machines were not assessed as part of its registration.

4.8 Adverse Effects (Undesirable Effects)

Transient mild to moderate erythema was observed at the site of application in the majority of patients at some time during treatment.
The following adverse events were observed during clinical trials with Androderm.
Events are listed within body systems and categorised by frequency according to the following definitions: very common events reported at a frequency of greater or equal to 1/10 patients; common events reported at a frequency of less than 1/10 but greater or equal to 1/100 patients; uncommon events reported at a frequency of less than 1/100 but greater or equal to 1/1,000 patients; rare events reported at a frequency of less than 1/1,000 but greater than or equal to 1/10,000 patients; very rare events reported at a frequency of less than 1/10,000 patients.

Body as a whole.

Common: Headache.
Uncommon: Body pain, accelerated growth, depression, fatigue, confusion, increased appetite, decreased libido, thinking abnormalities, pelvic pain.

Cardiovascular system.

Uncommon: Hypertension, peripheral vascular disease.

Central and peripheral nervous system.

Uncommon: Vertigo, paraesthesia.


Common: Gastrointestinal bleeding.


Uncommon: Anxiety.


Common: Prostatic abnormalities.
Uncommon: Impotence, testicular abnormalities. There was a single case of prostatic carcinoma.


Very common: Pruritus at application site, burn-like blister reaction under system.
Common: Erythema at application site, vesicles at application site, allergic contact dermatitis to the system, rash, induration at application site, burning at application site.
Uncommon: Acne, bullae at application site, mechanical irritation at application site, rash at application site, contamination at application site.

Urinary tract system.

Uncommon: Urinary tract infection, dysuria, urinary incontinence, haematuria.

Skin irritancy.

Three types of application site reactions occurred: irritation which included mild to moderate erythema, induration or burning; allergic contact dermatitis; and burn-like blister reactions.
Chronic skin irritation caused 5% of patients to discontinue treatment. Mild skin irritation may be ameliorated by treatment of affected skin with over the counter topical hydrocortisone cream or topical antihistamine products.
Five patients (4%) developed allergic contact dermatitis after 3 to 8 weeks treatment that required discontinuation. These reactions were characterised by pruritus, erythema, induration and in some instances vesicles or bullae, which recurred with each system application. Re-challenge with components of the system showed ethanol sensitisation in four patients. One patient's reaction was attributed to testosterone. None of these patients had adverse sequelae related to oral alcohol ingestion or to injectable testosterone use. Older patients may be more prone to develop allergic contact dermatitis.
Fourteen patients (12%) had burn-like blister reactions that involved bullae, epidermal necrosis or the development of ulcerated lesions. These reactions typically occurred once, at a single application site; five patients experienced a single recurrence. None withdrew from the clinical trials. These reactions occurred at a rate of approximately 1 in 6,500 system applications (1 in 3,250 treatment days). The majority of these lesions were associated with system application over bony prominences or on parts of the body that may have been subject to prolonged pressure during sleep or sitting (e.g. over the deltoid region of the upper arm, the greater trochanter of the femur, or the ischial tuberosity). The more severe lesions healed over several weeks with scarring in some cases. Such lesions could be treated as burns.
Other known undesirable effects associated with testosterone treatments include male pattern baldness, seborrhoea, excessive frequency and duration of penile erections and nausea.
Oligospermia may occur at high doses.
Prolonged testosterone administration may cause electrolyte disturbances, e.g. retention of sodium, chloride, potassium, calcium, inorganic phosphates and water.
Post marketing reports of venous thromboembolism.
Weight increased.

Reporting suspected adverse effects.

Reporting suspected adverse reactions after registration of the medicinal product is important. It allows continued monitoring of the benefit-risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions at

4.9 Overdose

This is not likely due to the mode of administration. Serum testosterone has a half-life of 70 minutes and therefore falls rapidly once patches are removed.
For information on the management of overdose, contact the Poisons Information Centre on 13 11 26 (Australia).

5 Pharmacological Properties

5.1 Pharmacodynamic Properties

Mechanism of action.

Androderm delivers physiological amounts of testosterone producing circulating testosterone concentrations that mimic the normal circadian rhythm of healthy young men.
Testosterone, the primary androgenic hormone, is responsible for the normal growth and development of the male sex organs and for maintenance of secondary sex characteristics. Male hypogonadism results from insufficient secretion of testosterone and is characterised by low serum testosterone concentrations.
Symptoms associated with male hypogonadism include the following: impotence and decreased sexual desire; fatigue and loss of energy; mood depression; regression of secondary sexual characteristics.
Androgens promote retention of nitrogen, sodium, potassium and phosphorus, decrease urinary excretion of calcium and increase bone mass, increase protein anabolism, decrease protein catabolism, and stimulate muscle growth. They are also responsible for the growth spurt of adolescence and for the eventual termination of linear growth and stimulate the production of red blood cells by enhancing erythropoietin production.
Exogenous administration of androgens inhibits endogenous testosterone release. With large doses of exogenous androgens, spermatogenesis may be suppressed.

Clinical trials.

Normal range morning serum testosterone concentrations are reached during the first day of dosing. There is no accumulation of testosterone during continuous treatment.
The average morning level of testosterone was 589 ± 209 nanogram/dL (normal range 306 to 1031 nanogram/dL). For bioavailable testosterone, dihydrotestosterone and estradiol, values were normalised in 88%, 85% and 77% of patients respectively.
In hypogonadal men, application of two Androderm 2.5 mg/day Transdermal Patches to the back, abdomen, thighs or upper arms resulted in average testosterone absorption of 4 to 5 mg over 24 hours. The serum testosterone concentration profiles during application were similar for these sites. Applications to the chest and shins resulted in greater inter individual variability and average 24 hour absorption of 3 to 4 mg.
Upon removal of the Androderm Transdermal Patches, serum testosterone concentrations decrease with an apparent half-life of approximately 70 minutes. Hypogonadal concentrations are reached within 24 hours following system removal.
In a study of 20 hypogonadal patients, two Androderm 2.5 mg/day Transdermal Patches and a single Androderm 5 mg/day Transdermal Patch produced equivalent serum testosterone concentration profiles. Average steady state concentrations over 24 hours (Cssavg) were 613 ± 169 and 621 ± 176 nanogram/dL for the two 2.5 mg and single 5 mg systems, respectively. Cmax values were 925 ± 340 nanogram/dL for the two 2.5 mg systems and 905 ± 254 nanogram/dL for the single 5 mg system. Although not statistically significant, more subjects reported adverse reactions with the 5 mg patch than with two 2.5 mg patches. These adverse events included redness, itching and skin irritation at the patch site.
Androderm therapy suppresses endogenous testosterone secretion via the pituitary/gonadal axis, resulting in a reduction in baseline serum testosterone concentrations compared to the untreated state.

5.2 Pharmacokinetic Properties

Following Androderm application to nonscrotal skin, testosterone is continuously absorbed during the 24 hour dosing period. The interaction between the testosterone gel formulation and the skin is rate limiting to the systemic absorption of testosterone.
Daily application of Androderm at approximately 10 pm results in a serum testosterone concentration profile which mimics the normal circadian variation observed in healthy young men. Figure 1 shows maximum concentrations occur in the early morning hours with minimum concentrations in the evening.

5.3 Preclinical Safety Data


No data available.


The potential carcinogenicity of testosterone has been tested by subcutaneous injection and implantation in mice and rats. In mice, the implant induced cervical uterine tumours, which metastasised in some cases. There is suggestive evidence that injection of testosterone in some strains of female mice increases their susceptibility to hepatoma. Testosterone is also known to increase the number of tumours and decrease the degree of differentiation of chemically induced carcinomas of the liver in rats.
There are rare reports of hepatocellular carcinoma in patients receiving long-term therapy with androgens in high doses. Withdrawal of the drugs did not lead to regression of the tumours in all cases.
Chronic androgen deficiency, however, is a protective factor for prostatic disease and hypogonadal men receiving androgen replacement therapy require surveillance for prostate disease similar to that recommended for eugonadal men of comparable age. Geriatric patients treated with androgens may be at an increased risk for the development of prostatic hyperplasia and prostatic cancer.

6 Pharmaceutical Particulars

6.1 List of Excipients

Each patch also contains ethanol, purified water, glycerol, glyceryl monooleate, methyl laurate, carbomer copolymer (Type B), and sodium hydroxide as excipients in the drug reservoir.

6.2 Incompatibilities

Incompatibilities were either not assessed or not identified as part of the registration of this medicine.

6.3 Shelf Life

In Australia, information on the shelf life can be found on the public summary of the Australian Register of Therapeutic Goods (ARTG). The expiry date can be found on the packaging.

6.4 Special Precautions for Storage

Store below 25°C. The drug reservoir may be burst by excessive heat or pressure. Apply to skin immediately upon removal from the protective pouch. Do not store outside the pouch provided.

6.5 Nature and Contents of Container

Each Androderm 2.5 mg/day Transdermal Patch contains 12.2 mg testosterone USP for delivery of 2.5 mg testosterone per day. Each patch is individually pouched and supplied in cartons of 30 and 601.
Each Androderm 5 mg/day Transdermal Patch contains 24.3 mg testosterone USP for delivery of 5 mg testosterone per day. Each patch is individually pouched and supplied in cartons of 5 and 301.
1 Not all pack sizes and strengths may be available.

6.6 Special Precautions for Disposal

Androderm may be discarded with household waste in a manner that avoids accidental contact by others.

6.7 Physicochemical Properties

Chemical structure.

CAS number.


7 Medicine Schedule (Poisons Standard)

S4 Prescription Only Medicine.

Summary Table of Changes